Search

The article discusses research on the efficacy of ZD4054 in prostate cancer presented during the 2008 Genitourinary Cancers Symposium in San Francisco, California from February 14 to 16, 2008. According to the study by Dr. Nancy Dawson and colleagues at the Prostace Center of Lombardi Comprehensive Cancer Center at Georgetown University, survival in patients with metastatic hormone-resistant prostate cancer given the investigational endothelin receptor antagonist from AstraZeneca improved. The study involved 312 patients.

The article discusses research on two chemotherapy regimens for patients with advanced urothelial cancer presented during the 2008 Genitourinary Cancers Symposium in San Francisco, California from February 14 to 16, 2008. According to the study by Dr. Maria De Santis and colleagues at Kaise Franz Josef-Spital, activities were observed in patients who underwent gemcitabine with carboplatin therapy and methoxerate, carboplatin and vinblastine (M-CAVI) treatment. All patients involved were not eligible for cisplatin therapy.